alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › glp-1-receptor

glp-1-receptor

3 studies tagged glp-1-receptor, dated 2017-12-07 to 2023-09-13. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer's disease models: a systematic review and meta-analysis of preclinical studies 2023-09-13
  2. Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R/Akt/GSK3β signaling 2019-04-20
  3. GLP-1 receptor agonists downregulate aberrant GnT-III expression in Alzheimer's disease models through the Akt/GSK-3β/β-catenin signaling 2017-12-07

Studies

3 studies carry this tag.

Date range

2017 to 2023

Top journals

  • Neuropharmacology 2
  • Frontiers in pharmacology 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer's disease models: a systematic review and meta-analysis of preclinical studies

    ✓ Peer-reviewed alzhub usefulness score 71 out of 100. Frontiers in pharmacology 2023-09-13 Drug development

    Alzheimer's disease (AD) is a degenerative disease of the nervous system.

  2. Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R/Akt/GSK3β signaling

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuropharmacology 2019-04-20 Drug development

    Diabetic retinal neurodegeneration, in particular synaptic neurodegeneration of retinal ganglion cells (RGCs) occurring before RGCs apoptosis, may represent the earliest event in the pathogenesis of diabetic retinopathy (DR).

  3. GLP-1 receptor agonists downregulate aberrant GnT-III expression in Alzheimer's disease models through the Akt/GSK-3β/β-catenin signaling

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Neuropharmacology 2017-12-07 Drug development

    Alterations of glycoprotein glycans contribute to a wide variety of diseases.

All topic tags with their study counts